User talk:PageMaster

Welcome

Hello, PageMaster, and Welcome to Wikipedia!

Welcome to Wikipedia! I hope you enjoy the encyclopedia and want to stay. As a first step, you may wish to read the Introduction.

If you have any questions, feel free to ask me at my talk page – I'm happy to help. Or, you can ask your question at the New contributors' help page.

Here are some more resources to help you as you explore and contribute to the world's largest encyclopedia...

Finding your way around:

Table of contents / Department directory

The Wikipedia Adventure (a tutorial orienting you with Wikipedia)

Need help?

Questions – a guide on where to ask questions
Cheatsheet – quick reference on Wikipedia's mark-up codes
Wikipedia's 5 pillars – an overview of Wikipedia's foundations

Article wizard – a Wizard to help you create articles
The simplified ruleset – a summary of Wikipedia's most important rules
Guide to Wikipedia – a thorough step-by-step guide to Wikipedia

How you can help:

Contributing to Wikipedia – a guide on how you can help

Community portal – Wikipedia's hub of activity

Additional tips...

Please sign your messages on talk pages with four tildes (~~~~). This will automatically insert your "signature" (your username and a date stamp). The or button, on the tool bar above Wikipedia's text editing window, also does this.
If you would like to play around with your new Wiki skills without changing the mainspace, the Sandbox is for you.

PageMaster, good luck, and have fun. — JJMC89 (T·C) 22:51, 5 November 2017 (UTC)[reply]

GCMaf edits

You need to add references to your GcMAF edits, and also explain how EF-022 = GcMAF (with references). --sciencewatcher (talk) 04:37, 8 November 2017 (UTC)[reply]

PageMaster says:

I'm new as an editor on Wikipedia and do not know how to do references yet. Maybe you can help me on that since the information I have posted is correct and the latest on GcMAF. The information from previous contributors is now out of date and incorrect. The Efranat Ltd Phase 1 Trial proved GcMAF to be safe at extremely high concentrations. Also the results of the trial proved that GcMAF can have a strong effect on some cancers. This information now is irrefutable. The FDA does not give orphan drug status to something that does not work for chronic viral diseases.

The article only focuses on cancer but GcMAF also attacks viral diseases like RRP. The article is too narrow if it just discusses cancer.

The basic patents that Efranat Ltd holds for making their EF-022 GcMAF product were secured from Dr. Yamamoto. Dr. Yamamoto was one of the 3 original founding partners in Efranat Ltd and was on the board of directors. There is no question if you look at the patents that Efranat Ltd hold that this is Dr. Yamamoto's GcMAF. So the completed Phase 1 trial proves that the criticism of his GcMAF are wrong. These critisms may apply to the lab production of GcMAF if the labs are not following cGMP's but this does not affect the potential medical uses of GcMAF per se. You don't throw the baby out with the bath water which the previous contributors did in denouncing GcMAF. Efranat Ltd is on the path to straighten this misconception out.

Try to help me with the references. The information without my contribution is outdated and incorrect. Do you want to continue to mislead the world about GcMAF? When you take my posting down you are doing that. Spreading wrong information. Help me with the references. Just look at the Trial, look at the Efranat Ltd website, look at the Efranat Ltd company page on Linkedin, Dr. Yamamoto's original patents are on the web and they show that the current holder is Efranat Ltd. I'm just trying to correct the record.

I have used GOleic (someone elses GcMAF) off and on for years to prevent prostste cancer which runs in my family and I know it works since at age 72 I do not have this cancer when it usually strikes my family members at a much earlier age. I get about 2 Nagalase Blood Tests per year to monitor this problem.